Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.

Turtle, Cameron J.; Berger, Carolina; Sommermeyer, Daniel; Budiarto, Tanya M; Hanafi, Laïla-Aïcha; Melville, Katherine M.; Pender, Barbara S.; Steevens, Natalia N; Chaney, Colette; Heimfeld, Shelly; Cherian, Sindhu; Wood, Brent L.; Soma, Lori; Chen, Xueyan; Jensen, Michael C.; Riddell, S.; Maloney, David G.

doi:10.1200/jco.2015.33.15_suppl.3006

Cited by 20 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small pilot study of CART19 in combination with IL-2 in patients with relapsed or refractory B-NHL showed encouraging preliminary activity [65]. Ongoing trials using CART19 in B-NHL have now presented interim results and confirmed the preliminary efficacy and safety of this treatment strategy in B-cell lymphomas [66][67][68]. CD20-specific CAR-T (CART20) has also now been developed and preliminary results from an ongoing trial have been published [69].…”

Section: Chimeric Antigen Receptor-modified T-cell Therapy In B-nhlmentioning

confidence: 96%

Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma

Villasboas¹,

Ansell²

2015

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Section: Chimeric Antigen Receptor-modified T-cell Therapy In B-nhlmentioning

confidence: 96%

Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma

Villasboas¹,

Ansell²

2015

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

“…A first step to optimize CAR T-cell therapy will require homogenizing cell products by better defining their composition. Not only this reduces variability between patients, but defined ratios of T-cell subtypes also seem to drive better CAR T-cell proliferation and persistence [49]. Innovative gene-editing platforms, such as CRISPR-Cas9, will also help achieving better and more stable expression of the CAR.…”

Section: Increasing Car T-cells Persistencementioning

confidence: 98%

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives

Gauthier

Yakoub-Agha

2017

Current Research in Translational Medicine

View full text Add to dashboard Cite

“…Incorporating tumour-reducing chemotherapy as well as lymphodepleting chemotherapy before CAR-T-cell infusion might improve the safety and efficacy profile of this treatment by reducing the numbers of reactive inflammatory cells in the tumour microenvironment and creating a niche for CAR-T-cell expansion and subsequent persistence 50,51,73 .…”

Section: Engineered Car T Cellsmentioning

confidence: 99%

“…Another alternative approach is to infuse patients with polyspecific CAR T cells that targets multiple cell-surface proteins to prevent immune escape. Methods to increase persistence of CAR T cells to promote treatment efficacy include using allogeneic virus-specific T cells and a combination of CD8-positive central memory T cells and CD4-positive T cells 27,87,88 . Off-the-shelf CAR T cells that are matched to the recipient by HLA typing can reduce time and resource constraints of using CAR T cells 89 .…”

Section: Engineered Car T Cellsmentioning

confidence: 99%

Novel immunotherapies in lymphoid malignancies

et al. 2015

View full text Add to dashboard Cite

The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid malignancies provided proof-of-principle for exploiting the immune system therapeutically. Since the FDA approval of rituximab in 1997, several novel strategies that harness the ability of T cells to target cancer cells have emerged. Reflecting on the promising clinical efficacy of these novel immunotherapy approaches, the FDA has recently granted ‘breakthrough’ designation to three novel treatments with distinct mechanisms. First, chimeric antigen receptor (CAR)-T-cell therapy is promising for the treatment of adult and paediatric relapsed and/or refractory acute lymphoblastic leukaemia (ALL). Second, blinatumomab, a bispecific T-cell engager (BiTE®) antibody, is now approved for the treatment of adults with Philadelphia-chromosome-negative relapsed and/or refractory B-precursor ALL. Finally, the monoclonal antibody nivolumab, which targets the PD-1 immune-checkpoint receptor with high affinity, is used for the treatment of Hodgkin lymphoma following treatment failure with autologous-stem-cell transplantation and brentuximab vedotin. Herein, we review the background and development of these three distinct immunotherapy platforms, address the scientific advances in understanding the mechanism of action of each therapy, and assess the current clinical knowledge of their efficacy and safety. We also discuss future strategies to improve these immunotherapies through enhanced engineering, biomarker selection, and mechanism-based combination regimens.

show abstract

Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.

Cited by 20 publications

References 0 publications

Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma

Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives

Novel immunotherapies in lymphoid malignancies

Contact Info

Product

Resources

About